Company Profile for Zila, Inc.Zila, Inc. develops and markets preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Its three business units are: Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection; Zila Pharmaceuticals, a marketer of products to promote oral health and prevent oral disease; and Zila Nutraceuticals, a manufacturer and marketer of advanced protection vitamins. Brands include Zila(R) Tolonium Chloride tolonium chloride see toluidine blue. (ZTC ZTC Zonal Training Centre (Africa) ZTC Zero Temperature Coefficient ZTC Zerotree Children ZTC Zero Touch Configurator ZTC Zero Tree Coding (TM)) and OraTest(R) (Biotechnology); ViziLite(R), Peridex(R), and Zilactin(R) (Pharmaceuticals); and Ester-C(R) and Ester-E(R) (Nutraceuticals). Zila recently received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance to market its patented ZTC product as an adjunct to its ViziLite product for oral cancer detection. In what the company believes is a significant event in the fight against oral cancer, ZTC will be used to mark for further evaluation abnormalities identified by ViziLite. The official launch of the identification and marking system will coincide with the annual meeting of the American Dental Association American Dental Association (ADA), n.pr a nonprofit professional association whose membership is dental professionals in the United States. Its purpose is to assist its members in providing the highest professional and ethical care to the citizens of the in October 2005. In a related development, Zila announced that, following comments from the FDA regarding proposed amendments aimed at simplifying and expediting a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical program of its OraTest product (whose active pharmaceutical ingredient is ZTC), it has decided to proceed with certain preliminary processes necessary to conduct the program; these will include submission of clinical protocols to independent review boards (IRBs) and completion of requisite contractual agreements. In requesting the amendments, the company seeks to include severe dysplasia dysplasia Abnormal formation of a bodily structure or tissue, usually bone, that may occur in any part of the body. Several types are well-defined diseases in humans. , a recognized precursor precursor /pre·cur·sor/ (pre´kur-ser) something that precedes. In biological processes, a substance from which another, usually more active or mature, substance is formed. In clinical medicine, a sign or symptom that heralds another. to cancer, as a true positive finding and in so doing better assess the efficacy of OraTest in the early detection of oral cancers.
Company: Zila, Inc.
Headquarters Address: 5227 North 7th Street
Phoenix, AZ 85014
Main Telephone: 602-266-6700
Website: http://www.zila.com
Ticker: ZILA(NASDAQ)
Type of Organization: Public
Industry: Bio-tech; pharmaceutical; nutraceutical
Key Executives: CEO: Douglas Burkett
CFO: Andrew Stevens
Investor Relations
Contact: Andrew Stevens
Phone: 602-266-6700
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion